A pilot study of Livin gene and Yes-associated protein 1 expression in hepatocellular carcinoma patients

Badr, Eman; Sayed, Ibrahim El Tantawy El; Assar, Mona Ali Mahmoud; Ali, Sahar A. M.; N, Ibrahim

doi:10.1016/j.heliyon.2019.e02798

Cited by 3 publications

(4 citation statements)

References 36 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human BIRC7 is encoded by BIRC7 (OMIM#: 605737) gene that positioned on chromosome 20q13.33 and spanned nearly 4613 bases. The BIRC7 gene consists of seven exons with six introns [12]. Based on the genomic structure of the livin/BIRC7 In general, as most IAPs, BIRC7 expression was not noticeable in normal differentiated adult tissues, except placenta, spleen, lymph nodes, and developing embryonic tissues [13].…”

Section: Introductionmentioning

confidence: 99%

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

Elmekkawy

Shoaib

Seleem

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process. This case-control study was intended to investigate livin/BIRC7 gene expression in endometrial hyperplasia and carcinoma and its correlation to some oxidative stress markers in addition to its possible diagnostic performance. Methods This study included 90 participants [30 endometrial hyperplasia patients, 30 endometrial carcinoma patients, and 30 healthy controls]. Livin/BIRC7 gene expression was analyzed using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Serum catalase activity was assessed by enzyme-linked immunosorbent assay (ELISA) and malondialdehyde level was measured by the colorimetric method. Results Livin/BIRC7 gene expression was significantly (p < 0.001) higher in endometrial carcinoma from patients with endometrial hyperplasia when compared to controls. A positive correlation was found between livin/BIRC7 expression and serum catalase activity and malondialdehyde level in endometrial hyperplasia and carcinoma. The detection of livin/BIRC7 in endometrial carcinoma has excellent sensitivity and specificity. Conclusions Livin/BIRC7 was overexpressed in endometrial carcinoma with excellent power to differentiate endometrial carcinoma from endometrial hyperplasia or healthy subjects, suggesting that it might be a useful molecular marker for endometrial carcinoma diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

Elmekkawy

Shoaib

Seleem

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

show abstract

“…According to reports, Livin's anti-apoptotic mechanism is mainly inhibiting the activity of the mitochondrial apoptotic signaling pathway molecules caspase 3, 7 and 9. They can activate transforming growth factor β-activated kinase1 and its binding protein to mediate mitogen-activated protein kinases pathways, and play the role of apoptosis mediated by tumor necrosis factor-alpha and interleukin 1β converting enzyme [7]. In addition, Livin can inhibit E3 ubiquitin ligase-like activity.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, Livin can inhibit E3 ubiquitin ligase-like activity. It promotes the degradation of Smac / DIABLO, which is a key endogenous regulator of all IAPs [7]. It has been proved that Livin can improve the viability of cancer cells, and make it easy for cancer cells to avoid immune surveillance and cytotoxin effects.…”

Section: Discussionmentioning

confidence: 99%

“…This difference lies between the baculoviral IAPs repeat and ring zinc nger-like domains [3]. Livin gene is lowly expressed in most normal tissues, and highly expressed in most malignant tumors, such as ovarian cancer, head and neck squamous cell carcinoma, malignant melanoma [4][5][6][7][8]. The high expression of Livin in most tumors is associated with more aggressive biological behavior, chemotherapy resistance and poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RNA Interference Mediates Livin Gene Silencing to Enhance Chemosensitivity of Pancreatic Adenocarcinoma in Vitro

Liu¹,

Wang²,

Yang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose RNA interference (RNAi) was used to silence the expression of Livin gene in human pancreatic adenocarcinoma cell line (PANC1), and to investigate the chemosensitivity of PANC1on gemcitabine after the Livin gene knockdown.Methods Using LipofectamineTM2000 as a carrier, a small interfering RNA (siRNA) targeting Livin gene was transfected into PANC1 cells. The mRNA and protein expression of Livin, cleaved PARP (cPARP) and caspase-3 (cCaspase-3) in PANC1 cells were measured by RT-PCR and Western Blot. The protein bands density was analyzed by Image J software, and expressed by the density ratio with the corresponding internal control protein (β-actin). The density ratios of the cPARP and cCaspase-3 protein bands were analyzed by one-way analysis of variance and Student's t-test for comparison of multiple or two groups. A p < 0.05 was considered statistically significant.Results Livin mRNA expression of PANC1 cells significantly decreased after transfection with Livin-siRNA # 1. The cPARP and cCaspase-3 induced by 50 nM gemcitabine were stronger than those induced by 25 nM after 48 hours and 72 hours in PANC1 cells.But the cPARP and cCaspase-3 induced by 100 nM gemcitabine did not significantly change compared with 50 nM. After transfection of Livin-siRNA # 1, cPARP and cCaspase-3 induced by both 25 nM and 50 nM gemcitabine were enhanced. This indicated that the apoptosis of PANC1 cells induced by gemcitabine was enhanced after Livin knockdown.Conclusions RNAi-targeted Livin promotes apoptosis of PANCl cells in vitro through PARP and caspase-3 pathways, and enhances its chemosensitivity to gemcitabine.

show abstract

Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)

Li,

Hao,

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

The Hippo signaling pathway plays a pivotal role in regulating cell growth and organ size. Its regulatory effects on hepatocellular carcinoma (HCC) encompass diverse aspects, including cell proliferation, invasion and metastasis, tumor drug resistance, metabolic reprogramming, immunomodulatory effects and autophagy. Yes-associated protein 1 (YAP1), a potent transcriptional coactivator and a major downstream target tightly controlled by the Hippo pathway, is influenced by various molecules and pathways. The expression of YAP1 in different cell types within the liver tumor microenvironment exerts varying effects on tumor outcomes, warranting careful consideration. Therefore, research on YAP1-targeted therapies merits attention. This review discusses the composition and regulation mechanism of the Hippo/YAP1 signaling pathway and its relationship with HCC, offering insights for future research and cancer prevention strategies.

show abstract

A pilot study of Livin gene and Yes-associated protein 1 expression in hepatocellular carcinoma patients

Cited by 3 publications

References 36 publications

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

RNA Interference Mediates Livin Gene Silencing to Enhance Chemosensitivity of Pancreatic Adenocarcinoma in Vitro

Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)

Contact Info

Product

Resources

About